283 related articles for article (PubMed ID: 34875139)
1. Efficacy of QR678 Neo
Shome D; Kapoor R; Surana M; Vadera S; Shah R
J Cosmet Dermatol; 2022 Jan; 21(1):16-23. PubMed ID: 34875139
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS-A prospective study.
Kapoor R; Shome D; Doshi K; Patel G; Vadera S
J Cosmet Dermatol; 2020 Oct; 19(10):2637-2646. PubMed ID: 33460214
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy of QR678
Kapoor R; Shome D; Doshi K; Vadera S; Patel G; Kumar V
J Cosmet Dermatol; 2020 Dec; 19(12):3270-3279. PubMed ID: 33016514
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo
Clinic A; Asper A; Mittal A; Shome D; Parbhoo D; Thanzama J; Doshi K; Sachde N; Gaunkar R; Kapoor R; Thakkar R; Sion S; Shetty S; Kumar V; Parveen V; Singhal V
J Cosmet Dermatol; 2022 Feb; 21(2):580-589. PubMed ID: 34997995
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of QR678 and QR678 Neo
Shome D; Kapoor R; Doshi K; Patel G; Vadera S; Kumar V
J Cosmet Dermatol; 2022 Jan; 21(1):358-367. PubMed ID: 34825770
[TBL] [Abstract][Full Text] [Related]
6. QR 678 & QR678 Neo Vs PRP-A randomised, comparative, prospective study.
Kapoor R; Shome D; Vadera S; Ram MS
J Cosmet Dermatol; 2020 Nov; 19(11):2877-2885. PubMed ID: 32333510
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo
Shome D; Kapoor R; Vadera S; Doshi K; Patel G; Mohammad Khan T
J Cosmet Dermatol; 2021 Oct; 20(10):3299-3307. PubMed ID: 33826786
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 infection is a major cause of acute telogen effluvium.
Sharquie KE; Jabbar RI
Ir J Med Sci; 2022 Aug; 191(4):1677-1681. PubMed ID: 34467470
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?
Koç Yıldırım S; Erbağcı E; Demirel Öğüt N
J Cosmet Dermatol; 2022 May; 21(5):1809-1815. PubMed ID: 35201647
[TBL] [Abstract][Full Text] [Related]
10. Red LED light therapy for telogen effluvium in the course of long COVID in patients with and without androgenetic alopecia.
Gerkowicz A; Bartosińska J; Krakowski P; Karpiński R; Krasowska D; Raczkiewicz D; Kwasny M; Krasowska D
Ann Agric Environ Med; 2024 Jun; 31(2):239-247. PubMed ID: 38940108
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation.
Hussain N; Agarwala P; Iqbal K; Omar HMS; Jangid G; Patel V; Rathore SS; Kumari C; Velasquez-Botero F; López GAB; Vishwakarma Y; Nipu AP; Ahmed NK
J Med Virol; 2022 Apr; 94(4):1391-1401. PubMed ID: 34931698
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial.
El-Dawla RE; Abdelhaleem M; Abdelhamed A
Indian J Dermatol Venereol Leprol; 2023; 89(2):195-203. PubMed ID: 35593290
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 induced telogen effluvium.
Aksoy H; Yıldırım UM; Ergen P; Gürel MS
Dermatol Ther; 2021 Nov; 34(6):e15175. PubMed ID: 34708909
[TBL] [Abstract][Full Text] [Related]
14. The role of autologous micrografts injection from the scalp tissue in the treatment of COVID-19 associated telogen effluvium: Clinical and trichoscopic evaluation.
Hawwam SA; Ismail M; Elhawary EE
Dermatol Ther; 2022 Jul; 35(7):e15545. PubMed ID: 35486375
[TBL] [Abstract][Full Text] [Related]
15. Post-COVID Telogen Effluvium.
Tešanović Perković D; Vukojević M; Bukvić Mokos Z
Acta Dermatovenerol Croat; 2022 Dec; 30(4):220-226. PubMed ID: 36919388
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study.
Milani M; Colombo F;
Skin Res Technol; 2023 Jun; 29(6):e13381. PubMed ID: 37357646
[TBL] [Abstract][Full Text] [Related]
17. Telogen effluvium and COVID-19: a cross-sectional study.
Aldahish A; Vasudevan R; Salem H; Alqahtani A; AlQasim S; Alqhatani A; Al Shahrani M; Al Mohsen L; Hajla M; Calina D; Sharifi-Rad J
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7823-7830. PubMed ID: 37667959
[TBL] [Abstract][Full Text] [Related]
18. Platelet-Rich Plasma Treatment for Accelerated Androgenetic Alopecia Pattern Hair Loss After COVID-19 Infection: A Case Series.
İşlek A; Karaaslan E; Şimşek S; Merve Çetin F
J Cosmet Dermatol; 2022 Feb; 21(2):590-594. PubMed ID: 34965004
[TBL] [Abstract][Full Text] [Related]
19. 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans.
Bleiker TO; Nicolaou N; Traulsen J; Hutchinson PE
Br J Dermatol; 2005 Jul; 153(1):103-12. PubMed ID: 16029334
[TBL] [Abstract][Full Text] [Related]
20. Topical odorant application of the specific olfactory receptor OR2AT4 agonist, Sandalore
Jimenez F; López E; Bertolini M; Alam M; Chéret J; Westgate G; Rinaldi F; Marzani B; Paus R
J Cosmet Dermatol; 2021 Mar; 20(3):784-791. PubMed ID: 32645251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
